Generic programmatic and clinical guide for the introduction of new drugs and shorter regimens for the treatment of Multi/Extensively Drug-Resistant TB

This document describes the steps necessary to implement the shorter regimen and the new drugs for drug-resistant TB treatment including diagnosis and bacterial confirmation of drug resistance, treatment regimen design, monitoring of treatment efficacy and safety, and programmatic evaluation.

KNCV has been fighting TB since its establishment in 1903. Over the past 120 years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework and integrity
Our patroness
Partner with us